A Phase I and Phase II Study of OSI-774 [erlotinib] in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck.
Phase of Trial: Phase I/II
Latest Information Update: 21 Nov 2013
At a glance
- Drugs Erlotinib (Primary) ; Docetaxel
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2007 Status changed from recruiting